What the zemprocitinib enrollment milestone means for Lynk Pharmaceuticals’ late-stage pipeline
Lynk Pharmaceuticals completes Phase III zemprocitinib enrollment as ASAS40 efficacy, long-term safety and China filing tests move closer.
Pharma & Biotech
Pharma & Biotech
Why Boehringer’s TL1A/IL23 bispecific bet could reshape IBD drug development
Find out why Boehringer is betting big on Simcere’s bispecific SIM0709 to challenge the IBD treatment ceiling.